Scarica l'app Stockscreener
99.85
2.44%
2.38
Dopo l'orario di chiusura:
99.98
0.13
+0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The National Law Review
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte (NASDAQ: INCY) grants CFO RSUs, options and performance shares - Stock Titan
MacroGenics and Sagard to expand Zynyz royalty purchase agreement - The Pharma Letter
Here's Why Incyte (INCY) is a Strong Growth Stock - Yahoo Finance
Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions - Barchart.com
Incyte Corp. Receives Positive Valuation Adjustment Amid Strong Financial Performance - Markets Mojo
INCY Reiterates by HC Wainwright & Co. -- Price Target Maintained at $135 - GuruFocus
Incyte (INCY) Partners with MacroGenics in Expanded Royalty Agre - GuruFocus
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term - Yahoo Finance
H.C. Wainwright Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $135 - Moomoo
New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1] - Quantisnow
INCY Q1 earnings and revenues beat estimates on higher product sales - MSN
Australia approves new therapy for transplant patients with chronic GVHD - Stock Titan
Incyte Corporation (NASDAQ:INCY) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Incyte (INCY) Positioned to Offset Patent Cliff Risks, Analysts Reaffirm Stock Ratings - Insider Monkey
Sanctuary Advisors LLC Has $3.16 Million Holdings in Incyte Corporation $INCY - MarketBeat
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extende - The National Law Review
Incyte gears up to report Q1 earnings: What can investors expect? - MSN
Incyte (INCY) Gains FDA Approval for Jakafi XR Treatment - GuruFocus
FDA approves Incyte’s once-daily Jakafi XR formulation - Investing.com
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease - Business Wire
Incyte: Strong Business, But Risks Remain (NASDAQ:INCY) - Seeking Alpha
Earnings Beat: Incyte Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
INCY SWOT Analysis: Strong Financial Performance Revealed in 10-Q Filing - GuruFocus
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Vanguard Capital Management (INCY) discloses 6.32% ownership in Incyte Corp - Stock Titan
GC Wealth Management RIA LLC Takes Position in Incyte Corporation $INCY - MarketBeat
Vanguard Group Inc. Sells 40,189 Shares of Incyte Corporation $INCY - MarketBeat
INCY Maintained by Oppenheimer -- Price Target Raised to $90 - GuruFocus
Stifel raises Incyte stock price target to $123 on earnings beat By Investing.com - Investing.com India
Stifel raises Incyte stock price target to $123 on earnings beat - Investing.com Australia
Incyte to Present at Upcoming May 2026 Investor Conferences - BioSpace
INCY Maintained by Stifel -- Price Target Raised to $123 - GuruFocus
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
Stifel Nicolaus Increases Incyte (NASDAQ:INCY) Price Target to $123.00 - MarketBeat
H.C. Wainwright reiterates Incyte stock rating on Jakafi outlook - Investing.com
Incyte Corporation (NASDAQ:INCY) Q1 2026 Earnings Call Transcript - Insider Monkey
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
Incyte Corp (INCY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Promising Pipeline Developments - GuruFocus
Latest INCY NewsBaricitinib has Significant Effect on Recov... - Stock Titan
INCY Financials: Income Statement, Balance Sheet & Cash Flow | Incyte Corp - Stock Titan
Morgan Stanley raises Incyte stock price target on solid results By Investing.com - Investing.com Nigeria
Oppenheimer raises Incyte stock price target on earnings beat By Investing.com - Investing.com South Africa
Oppenheimer raises Incyte stock price target on earnings beat - Investing.com
Morgan Stanley raises Incyte stock price target on solid results - Investing.com UK
Incyte Welcomes Suky Upadhyay as EVP, CFO - Contract Pharma
[ARS] INCYTE CORP SEC Filing - Stock Titan
Incyte (NASDAQ: INCY) posts 2025 growth, outlines pipeline and pay plan - Stock Titan
Robust Q1 2026 growth at Incyte (NASDAQ: INCY) driven by key drug sales - Stock Titan
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):